Project Grant K25CA301033
Award Date 9/17/25
Completion Date 8/31/30
Dollars Obligated $195K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The Department of Health and Human Services' National Cancer Institute awarded a $644,034 Project Grant on March 11, 2025 under the Cancer Treatment Research (CFDA 93.395) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant is for the development of a "scintillating nanoparticle drug depot (SCIDD) platform" that uses nanoparticles to convert X-ray energy into light, which can then release potent and tumor-penetrating...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $620,820.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of the transcription factor CREB5 in driving immune therapy resistance in cancer. The research aims to: 1) understand the molecular mechanisms governing CREB5 regulation and transcription, 2) identify CREB5-interacting proteins that drive collagen matrix...
- This federal Project Grant award of $684,107 from the National Cancer Institute (NCI), part of the Department of Health and Human Services, supports research to integrate circulating tumor cell (CTC) and nuclear imaging biomarkers to assess Lutetium-177 PSMA (Lu-PSMA) radiopharmaceutical therapy response and resistance in advanced prostate cancer patients. The research, conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to develop novel...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $176,040.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the effects of aging on CDC1 function and CD8 T cell immunity in tumors. The research aims to gain a better understanding of how age-related declines in immune function can impact the effectiveness of CD8+ T cell immunity and immunotherapy response in older cancer...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $198,000.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Precision Medicine for Non Small Cell Lung Cancer Brain Metastases: Noninvasive Detection of Targetable Mutations Using Radiosurgery." The award period runs from May 1, 2025 to April 30, 2026. As a renowned academic...
- This $231,413 federal Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on April 7, 2025. The grant supports a research project to establish in vitro models that recapitulate the carcinogenic process of human germ cell neoplasia in situ (GCNIS), which are precursor lesions for most testicular germ cell tumors. The project aims to...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,180,294 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to enhance precision oncology for underserved breast cancer patients through deep learning-aided histopathology analysis. The 3-year project, running from September 1, 2025 to August 31, 2028, aims to develop innovative diagnostic tools and therapeutic approaches...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $635,248 to Trustees of Boston University to develop a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BITE) antibody for the treatment of lung cancer. The key goals are to: Design 5-methylcytidine (5MC) modified SARNA constructs encoding BITE antibodies and evaluate their protein expression performance in vitro. Assess the in vitro and in...
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...
- This federal Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) provides $249,000.00 to the Regents of the University of California at Riverside to develop a novel "dual-barcoding" technology that utilizes laser particles with unique optical barcodes. This technology aims to enable the collection of live information on cells and connect that data to detailed omics information at the single-cell resolution....